An observational, prospective survey assessing the control of atrial fibrillation in Asia Pacific: Rationale and design of the RecordAF-AP registry

Clinical Medicine Insights: Cardiology

Volumn 5, Issue , 2011, Pages 1-6

  Amerena, John ^a   Chen, Shih Ann ^b   Sriratanasathavorn, Charn ^c   Cho, Jeong Gwan ^d   Dejia, Huang ^e   Omar, Razali ^f   Fat, Tse Hung ^g   King, Anthony ^h  

^a DEAKIN UNIVERSITY   (Australia)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Chonnam National University Medical School   (South Korea)

^e SICHUAN UNIVERSITY   (China)

^f NATIONAL HEART INSTITUTE   (Malaysia)

^g QUEEN MARY HOSPITAL   (Hong Kong)

^h MAKATI MEDICAL CENTER   (Philippines)

Author keywords

Atrial fibrillation; Cardiac glycosides; Rate control; RecordAF; Rhythm control; Sinus arrhythmia

Indexed keywords

AMIODARONE; SOTALOL;

ARTICLE; ASIA; AUSTRALIA; CHINA; CLINICAL ASSESSMENT TOOL; CONTROL STRATEGY; CONTROLLED STUDY; COST OF ILLNESS; DISEASE REGISTRY; FOLLOW UP; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HONG KONG; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALAYSIA; MEDICAL RECORD; OBSERVATIONAL STUDY; PATIENT CARE; PHILIPPINES; PROSPECTIVE STUDY; REGISTRY ON CARDIAC RHYTHM DISORDERS ASSESSING THE CONTROL OF ATRIAL FIBRILLATION ASIA PACIFIC; TAIWAN; THAILAND; TREATMENT OUTCOME;

EID: 79958190525     PISSN: 11795468     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.S6289     Document Type: Article

References (29)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995 Mar 13;155(5):469-73.
2. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-57.
3. Mathew J, Hunsberger S, Fleg J, Mc SF, Williford W, Yusuf S. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest. 2000 Oct;118(4):914-22.
4. Sanoski CA. Clinical, economic, and quality of life impact of atrial fibrillation. J Manag Care Pharm. 2009 Aug;15(6 Suppl B):S4-9.
5. Prystowsky EN, Camm J, Lip GY, Allessie M, Bergmann JF, Breithardt G, et al. The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. J Cardiovasc Electrophysiol. 2010 Apr 8.
6. Rich MW. Epidemiology of atrial fibrillation. J Interv Card Electrophysiol. 2009 Jun;25(1):3-8.
7. Freestone B, Rajaratnam R, Hussain N, Lip GY. Admissions with atrial fibrillation in a multiracial population in Kuala Lumpur, Malaysia. Int J Cardiol. 2003 Oct;91(2-3):233-8.
8. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5.
9. Yap KB, Ng TP, Ong HY. Low prevalence of atrial fibrillation in community- dwelling Chinese aged 55 years or older in Singapore: a population- based study. J Electrocardiol. 2008 Mar;41(2):94-8.
10. Jeong JH. Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40 years. J Korean Med Sci. 2005 Feb;20(1):26-30.
11. Zhou Z, Hu D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol. 2008;18(5):209-16.
12. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006 Sep;8(9):651-745.
13. Salam AM. Rate control versus rhythm control for the management of atrial ibrillation: the verdict of the AFFIRM trial. Expert Opin Investig Drugs. 003 Jul;12(7):1231-7.
14. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial ibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a andomised trial. Lancet. 2000 Nov 25;356(9244):1789-94.
15. Hagens VE, Ranchor AV, van SE, Bosker HA, Kamp O, Tijssen JG, et al. ffect of rate or rhythm control on quality of life in persistent atrial fibrillation. esults from the Rate Control Versus Electrical Cardioversion (RACE) tudy. J Am Coll Cardiol. 2004 Jan 21;43(2):241-7.
16. Van Gelder CI GHCHeal. Lenient versus strict rate control in patients with trial fibrillation. N Engl J Med. 2010 Mar 15.
17. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al. andomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003 May 21;41(10):1690-6.
18. Opolski G, Torbicki A, Kosior D, Szulc M, Zawadzka M, Pierscinska M, et al. Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study. Kardiol Pol. 2003 Jul;59(7):1-16.
19. de DS, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med. 2005 Feb 14;165(3):258-62.
20. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006 Apr 10;166(7):719-28.
21. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005 Nov;26(22):2422-34.
22. Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J. 2007 Jun; 153(6):1006-12.
23. Le Heuzey JY, Breithardt G, Camm J, Crijns H, Dorian P, Kowey PR, et al. The RecordAF study: design, baseline data, and profile of patients According to chosen treatment strategy for atrial fibrillation. Am J Cardiol. 010 Mar 1;105(5):687-93.
24. World Medical Association. Declaration of Helsinki: Ethical principles for edical research involving human subjects. Adopted 1964, last amended 004. Available from: http://www.wma.net/e/policy/b3.htm
25. International Epidemiological Association (IEA). Good Epidemiological ractice (GEP)-IEA Guidelines for proper conduct of epidemiological esearch. Available from: http://www.ieaweb.org
26. The EuroQol Group. EQ-5D: A standardised instrument for use as a measure f health outcome. Available from: www.euroqol.org/
27. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003 Jul 2;42(1):20-9.
28. Kowey PR, Breithardt G, Camm J, Crijns H, Dorian P, Le Heuzey JY, et al. Physician stated atrial fibrillation management in light of treatment guidelines: data from an international, observational prospective survey. Clin Cardiol. 2010 Mar 16;33(3):172-8.
29. Atrial fibrillation follow-up investigation of rhythm management-the AFFIRM study design. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Am J Cardiol. 1997 May 1; 79(9):1198-202.